* Genome Therapeutics Corp., of Waltham, Mass., received a $1.75million milestone payment from Schering-Plough Corp., of Madison,N.J. The milestone was achieved in their collaboration to discoveranti-infective agents against drug-resistant bacteria.

* Life Sciences Medical Inc., of Princeton, N.J., said preclinicalresults of Repel, the company's bioresorbable barrier for theprevention and reduction of post-operative adhesions, showed itoutperformed the only FDA-approved product for this application.

* Ligand Pharmaceuticals Inc., of San Diego, said Wyeth-AyerstLaboratories, of Philadelphia, exercised its option to expand theircollaboration to include the area of treatment or prevention ofosteoporosis through estrogen receptor agonists. Also, Wyeth-Ayerstelected to include four chemical compound series from its internalestrogen receptor osteoporosis program in the Ligand collaboration.The companies agreed on an undisclosed milestone and royaltyschedule for the additional series.

* Scientists from Ligand Pharmaceuticals Inc., of San Diego, and theInstitute Pasteur de Lille, of France, said they discovered thepromoter region responsible for controlling expression of the leptingene, which is implicated in obesity. Details of the findings werereported in the May 28, 1996, issue of the Proceedings of theNational Academy of Science.

* LXR Biotechnology Inc., of Richmond, Calif., said the combinationof hypothermia, preservation solution and LXR's candidate,LXR015, a modulator of apoptosis, resulted in significantly improvedfunction of donor organs following removal in a preclinical study.The trial was designed to determine if LXR's product can extendstorage time of donor organs prior to transplant.

* Neoprobe Corp., of Dublin, Ohio, filed a marketing application inEurope for RIGScan CR49, which is used to locate cancerous tissueduring surgery for colorectal cancer patients.

* NeXstar Pharmaceuticals Inc., of Boulder, Colo., was grantedmarketing authorization for DaunoXome as a primary therapy foradvanced AIDS-related Kaposi's sarcoma in Portugal, Greece,Ireland and Belgium.

* Paracelsian Inc., of Ithaca, N.Y., said encouraging results from aninitial compassionate use study of the anti-cancer drug PN 27, 1,resulted in expansion of the study to include 300 patients. Thecompany said strong responses were seen in six of seven patientsinitially treated.

* Periodontix Inc., of Watertown, Mass., completed a $3.5 millionprivate placement in its second round of financing. Among the usesfor the proceeds will be to initiate Phase I/II testing of P-113, anantimicrobial peptide derived from histatin proteins, which are foundin human saliva. The compound was efficacious in animal models ofgingivitis.

* Theratech Inc., of Salt Lake City, said its board approved a 3-for-2stock split. One additional share will be distributed on June 28, 1996,for each two shares held by stockholders on June 14, 1996.

(c) 1997 American Health Consultants. All rights reserved.